What matters here
The filed numbers show a business that has cut its losses by more than two-thirds as a share of revenue over five years, while growing sales at a pace most pharmaceutical companies would envy. The stock trades at a price-to-sales multiple, meaning the price per dollar of annual revenue, that sits near the bottom of its own history, according to our data. Those two readings pull in opposite directions, and the gap between them is the story.
From one product to a platform
Evolus launched Jeuveau, a botulinum toxin injectable competing directly with Botox, in 2019 with a single product and a single bet: that aesthetic practices would pay less for a comparable result. For three years the company bled cash at a rate that would alarm anyone watching. Then something changed. The fiscal year 2025 annual report shows total revenue of $297 million, more than five times what the company recorded in 2020, and a net loss that has shrunk from nearly three dollars lost per dollar earned to less than eighteen cents.
The math, meaning what the filed fundamentals actually show, is a business in the middle of a genuine transition. The mood, meaning what the market currently pays for that progress, is considerably more skeptical. Our data puts the current price-to-sales multiple at 1.6, against a historical median of 4.3 for this company. A business earning a dollar of revenue that once commanded more than four dollars in market value now commands less than two. That compression is either a warning or an opportunity, and the filings are the only place to look for clues.
What the most recent quarter actually shows
The Q2 2026 filing, covering the three months ended June 30, 2026, is the most recent period on record. Q3 results are scheduled for November 4, 2026, per a company announcement. So the freshest picture we have is about four months old, which matters for anyone trying to read the current state of the business.
In that quarter, total revenue reached $84 million, up roughly a fifth from the same quarter a year earlier. Jeuveau and its international equivalent, Nuceiva, contributed the large majority of that. The remainder came from Evolysse and Estyme, the company’s newer hyaluronic acid filler products, which are the injectable gels used to restore facial volume. A year ago those fillers barely registered. Now they represent roughly one dollar in ten of quarterly revenue, and the company expects that share to hold at a similar level for the full year.
Gross margin, the share of each revenue dollar left after the direct cost of making and delivering the product, reached 68% in Q2 2026, up from the prior quarter. Think of it this way: for every $100 a practice pays Evolus, about $68 is left to cover salaries, marketing, and everything else. That number has been climbing steadily, and the direction matters as much as the level.
The balance sheet: tighter than it looks
Cash stood at $45 million as of June 30, 2026, and the company used a modest amount in operating cash during the quarter. The company also disclosed approximately $120 million of additional borrowing capacity it describes as non-dilutive, meaning it would not require issuing new shares to raise the money. The Q2 10-Q confirms the company was in compliance with all debt covenants as of that date, and no going concern warning appears anywhere in the filing.
The revolving credit facility, a line of credit the company can draw on as needed, matures in March 2029. That structure gives Evolus flexibility without forcing it to sell shares at a price it may consider too low. For a company still running a net loss, that headroom is the difference between managing the transition on its own terms and being forced into a dilutive capital raise.
The risks the filing names plainly
Allergan, owned by AbbVie, holds the commanding majority of the global botulinum toxin market, according to a Seeking Alpha analysis citing March 2026 data, while Evolus holds a much smaller slice of the U.S. market. That gap is the structural ceiling on how fast Jeuveau can grow without either taking share directly from Botox or expanding the overall market.
Then there is the regulatory friction. On October 5, 2026, the FDA issued an untitled letter to Evolus, citing a misleading Instagram promotion for Jeuveau that overstated benefits and minimized risks. An untitled letter is the FDA’s least severe enforcement tool, but it signals that the agency is watching how the company markets its flagship product. For a brand built on digital-first outreach to millennial consumers, that is a constraint worth watching.
On the pipeline side, Evolus announced in October 2026 an option agreement for an injectable hair restoration program, with human trials not expected before 2028. That is a long horizon for a company still working toward consistent profitability, and the data cannot yet say whether the investment will prove well-timed or a distraction from the core business.
Reading the numbers
- Revenue, FY2025: $297 million. This is the total amount practices paid Evolus for its products over the year. It represents 12% growth over 2024, a slowdown from the 32% pace of the prior year. A business growing at 12% is growing roughly in line with a healthy economy, not at startup speed. The slowdown is the number to watch when Q3 2026 arrives on November 4.
- Net margin, FY2025: negative 17%. For every $100 of revenue, Evolus lost about $17 after all costs. Five years ago it lost $288 on the same $100. The direction is unambiguous; the destination, breakeven, is not yet in the filed numbers. A household analogy: imagine a small business that once spent $3.88 for every $1 it took in, and now spends $1.17. Still losing money, but the trajectory has changed completely.
- Gross margin, Q2 2026: 68%. This is what remains of each revenue dollar after the direct cost of the product itself. At 68%, Evolus keeps more of each sale than most consumer goods companies. The significance is that as revenue grows, more of each incremental dollar flows toward covering fixed costs, and eventually toward profit.
- Price-to-sales multiple: 1.6, versus a historical median of 4.3. A multiple is the price the market pays per dollar of annual revenue, a way of comparing price to scale. At 1.6, the market is paying $1.60 for each dollar of Evolus revenue. At the historical median of 4.3, it once paid $4.30. That gap reflects either a genuine reassessment of the business’s prospects or a lag between improving fundamentals and investor recognition. The filed numbers alone cannot resolve which.
- Cash runway: roughly 12 quarters at Q2 burn rate. At $3.6 million used per quarter, the $45 million cash balance covers about three years of operations at the current pace, before drawing on the $120 million in additional capacity. For context, that is enough time for the company to reach its own projected profitability milestones without necessarily needing to raise new money, though the Q3 filing will update this picture.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Evolus Q2 2026 earnings press release
- Q3 2026 results announcement (StockTitan)
- Evolus Q2 2026 10-Q (CloudFront/EDGAR)
- Seeking Alpha: Evolus injectable platform analysis
- Evolus pipeline expansion announcement, October 14, 2026
